As part of our integrated Pharmaceutical Development & Manufacturing offering, Viral Vector Development sits within Drug Substance Development. We provide phase-appropriate, laboratory-centered bioprocess development that transforms vector concepts into robust, well-characterized candidates, ready for orderly advancement within CMC frameworks and compatible with downstream quality expectations.
Overview of Viral Vector Development
Viral vectors are engineered delivery systems designed to package and deliver defined nucleic acid payloads to target cells with high specificity and efficiency. Common platforms—such as adeno-associated virus (AAV), lentiviral (LV), and adenoviral vectors—differ in payload capacity, duration of gene expression, and mechanisms of cell entry. In practice, vector platform development emphasizes rational genome design, including promoters, regulatory elements, and built-in safety features, alongside a clear understanding of vector–host interactions. This is supported by fit-for-purpose analytical methods that reliably assess identity, purity, potency, and stability, ensuring the vector is well characterized and suitable for downstream development.
Fig.1 Schematic diagram of viral vectors used to deliver genetic material into cells.
Our Services
We deliver AAV vector development, LV vector development and adenoviral vector development services. Each service includes genome and capsid/pseudotype strategy, producer-system selection, small-scale process prototyping, and a comprehensive analytical package.
We build development-grade viral vector platforms—AAV, LV, and Adenoviral—that are modular, analytically transparent, and engineered for reliable laboratory performance. By unifying genome design, bioprocess prototypes, and assay systems, we shorten iteration cycles and set clear paths for subsequent advancement. Contact us to scope your program.
Frequently Asked Questions
Q1: How do you recommend choosing between AAV, LV, and adenovirus for a new program?
We start with payload requirements, expression durability, and nonclinical model needs. AAV suits episomal persistence with a rich capsid toolbox; LV supports stable integration; adenovirus enables strong transient expression. We then prototype two candidates in parallel and let manufacturability and analytics guide the decision.
Q2: What are the primary quality attributes you target during early development?
We focus on identity (genome/capsid confirmation), purity (host and process residuals), potency (infectivity or transduction readouts), and structural integrity (empty/full ratio, aggregation). Each attribute is mapped to specific upstream/downstream levers and verified with orthogonal assays.
Q3: How do you assess genome integrity and minimize rearrangements or deletions?
We combine restriction patterning, sequencing-based checks, and functional expression assays. Upstream controls (plasmid quality, ITR handling, nuclease usage) and downstream conditions (shear exposure, buffer composition) are tuned to protect genomes while maintaining productivity.
Our products and services are for research use only.
